Compounded semaglutide is a category, not a product. Preparations differ by pharmacy, by salt form, by concentration, by excipients and by beyond-use dating. Understanding what quality testing has and has not established requires first understanding why the category is heterogeneous by construction.
Key Takeaways
- Compounded preparations are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing.
- 503A pharmacies compound for individually identified patients; 503B outsourcing facilities produce larger batches under CGMP-style requirements. The two are regulated differently.
- The FDA has publicly reported adverse events associated with compounded semaglutide, including dosing errors involving unit conversion.
- Salt forms — semaglutide sodium and semaglutide acetate — have been flagged by the FDA as different substances from the base semaglutide in approved products.
- Published independent analytical testing exists but is limited in scale and does not support generalization across the whole compounded market.
The regulatory architecture
Two categories of compounder operate under different sections of US law, and conflating them produces most of the confusion in this area.
503A pharmacies compound patient-specific preparations pursuant to a prescription for an identified individual. They are primarily state-regulated, are not required to comply with CGMP, and do not register products with the FDA.
503B outsourcing facilities may produce larger batches without patient-specific prescriptions, register with the FDA, are subject to FDA inspection, and must comply with CGMP requirements.
Neither category produces an FDA-approved drug. Approval is a distinct process involving pre-market review of safety and efficacy data, which compounded preparations do not undergo by definition.
The shortage-list mechanism and why it mattered
Compounding of a drug that is essentially a copy of an approved product is restricted. A widely used pathway during 2022–2025 was the drug shortage provision: when an approved drug appears on the FDA shortage list, compounding of preparations that would otherwise be prohibited becomes permissible under specified conditions.
Semaglutide and tirzepatide were on the shortage list during their supply-constrained period, which is what enabled the large compounded market to develop. Shortage resolution changed that permission structure and triggered the regulatory transition the market has been working through since. Separately, the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list in April 2026, with the comment period closing in June 2026. That rulemaking was not final as of this writing, and readers should verify its current status rather than rely on any summary.
What testing has been published
Analytical characterization of compounded peptide preparations has appeared in several forms: FDA statements and adverse-event reporting, testing commissioned by manufacturers of the approved products, and a smaller number of independent analyses.
The parameters that matter analytically are:
- Identity. Is the peptide present the intended sequence? Salt form is part of this question — the FDA has specifically noted that semaglutide sodium and semaglutide acetate are different substances from the semaglutide base used in approved products.
- Assay and content uniformity. Does the vial contain the labelled quantity, and is it consistent between vials and within a multi-dose vial across its use period?
- Impurities and degradation products. Peptides degrade through several pathways. Impurity profiles differ by source material and process.
- Sterility and endotoxin. Non-negotiable for injectables.
- Stability and beyond-use dating. Whether the assigned dating is supported by stability data for that specific formulation and container.
Published testing that addresses these parameters exists, but the sample sizes are small relative to the number of compounders in the market, and testing commissioned by parties with a commercial interest requires the same scepticism as any other interested-party evidence. The defensible summary is that quality varies and that no dataset supports a blanket claim in either direction about the market as a whole.
| Parameter | Verified pre-market for approved products? | Verified for a given compounded preparation? |
|---|---|---|
| Identity and salt form | Yes | Depends entirely on the individual pharmacy's practices |
| Content uniformity | Yes, under CGMP | Varies; 503B facilities operate under CGMP-style requirements, 503A do not |
| Impurity profile | Yes, with specified limits | Not standardized across the market |
| Sterility | Yes | Required, but verification practices vary |
| Stability / beyond-use dating | Yes, product-specific | Assigned by the compounder; supporting data varies |
| Clinical efficacy at the labelled dose | Yes | Not established for compounded preparations |
The dosing-error problem
Distinct from formulation quality, the FDA has reported adverse events involving dosing errors with compounded semaglutide. A recurring pattern involves unit confusion: patients drawing doses in insulin-syringe units and administering a multiple of the intended quantity, or errors arising when concentrations differ between suppliers.
This is a systems failure rather than a chemistry failure, and it is a foreseeable consequence of a market in which concentration is not standardized. Approved products are supplied in pens with fixed, dialled doses. A multi-dose vial plus a syringe transfers the arithmetic to the patient.
What is not established
- Clinical outcome equivalence. No randomized trial has compared a compounded preparation against an approved product for weight-loss outcomes. Efficacy data cited for compounded products is borrowed from trials of the approved products.
- Market-wide quality distribution. Published testing samples a small fraction of compounders. Generalizing from it in either direction is unsupported.
- Long-term safety of specific impurity profiles. Impurities that differ from those in approved products have no long-term human exposure data.
Frequently Asked Questions
Is compounded semaglutide the same drug as the approved product?
It contains a preparation intended to deliver semaglutide, but it is not the same product. It has not been through pre-market review, formulation and concentration differ by compounder, and salt forms used in some preparations have been identified by the FDA as different substances from the base used in approved products.
Does 503B registration mean a product is FDA-approved?
No. 503B outsourcing facilities register with the FDA and are subject to inspection and CGMP requirements, but their preparations are not FDA-approved drugs.
Has anyone tested compounded semaglutide independently?
Analytical testing has been published, including work commissioned by interested parties and a smaller body of independent analysis. The scale is limited relative to the size of the market.
What should a patient ask a compounding provider?
Which pharmacy compounds the preparation and whether it is 503A or 503B; what concentration is supplied and in what container; what salt form or base is used; what beyond-use date is assigned and on what basis; and whether certificates of analysis are available. A provider unwilling to answer these is itself informative.
References
- US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — agency statements and adverse event reporting.
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers; sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
- US Food and Drug Administration. Proposed rulemaking regarding the 503B bulk drug substances list, docket published April 2026 (status: not final as of publication).
- United States Pharmacopeia. General Chapters <797> Pharmaceutical Compounding — Sterile Preparations and <825> Radiopharmaceuticals.
Comparing providers, not just trials?
Our homepage keeps a maintained side-by-side grid of GLP-1 telehealth providers with current pricing, formats and disclosures. That is where the provider comparisons live — this research desk stays citation-first.
Open the provider comparison grid